For the quarter ending 2025-09-30, ABCL made $8,955K in revenue. -$57,160K in net income. Net profit margin of -638.30%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 8,955 | 17,084 | 4,235 | 6,227 |
| Research and development | 55,028 | 39,213 | 42,496 | 42,682 |
| Depreciation, amortization, and impairment | - | - | - | 8,705 |
| Sales and marketing | 2,906 | 3,009 | 2,842 | 3,254 |
| General and administrative | 22,052 | 18,977 | 16,226 | 16,686 |
| Depreciation, amortization, and impairment | 5,247 | 5,470 | 5,331 | - |
| Total operating expenses | 85,233 | 66,669 | 66,895 | 71,326 |
| Loss from operations | -76,278 | -49,585 | -62,660 | -63,824 |
| Interest income | 6,765 | 7,592 | 8,051 | 9,535 |
| Grants and incentives | 2,729 | 3,692 | 4,153 | 3,410 |
| Other | -1,984 | 1,957 | -2,528 | 6,093 |
| Total other income | 7,510 | 13,241 | 9,676 | 19,037 |
| Net loss before income tax | -68,768 | -36,344 | -52,984 | -44,788 |
| Income tax recovery | -11,649 | -1,617 | -7,363 | -7,378 |
| Net loss | -57,119 | -34,727 | -45,621 | -37,410 |
| Foreign currency translation adjustment | -41 | 4,341 | -2,620 | -1,621 |
| Comprehensive loss | -57,160 | -30,386 | -48,241 | -39,031 |
| Basic (in shares) | 298,875,174 | 298,508,601 | 297,692,663 | -147,370,713 |
| Basic (usd per share) | -0.19 | -0.12 | -0.15 | -0.125 |
| Diluted (in shares) | 298,875,174 | 298,508,601 | 297,692,663 | -147,370,713 |
| Diluted (usd per share) | -0.19 | -0.12 | -0.15 | -0.125 |
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)